射波刀与射频消融治疗小肝癌的近期效果比较

杨曌; 谢辉; 王权; 张弢; 王华明; 何卫平; 段学章

doi:10.3969/j.issn.1001-5256.2019.09.016

射波刀与射频消融治疗小肝癌的近期效果比较

DOI: 10.3969/j.issn.1001-5256.2019.09.016

1. 解放军医学院
2. 解放军总医院第五医学中心

基金项目:

首都特色基金(Z151100004015002)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1745
- HTML全文浏览量: 21
- PDF下载量: 283
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-10
- 出版日期: 2019-09-20

Short-term clinical effect of cyberknife versus radiofrequency ablation in treatment of small hepatocellular carcinoma

Medical School of Chinese PLA

Research funding:

摘要

摘要: 目的比较射波刀与射频消融治疗小肝癌的疗效及安全性。方法选取2017年10月-2018年3月解放军总医院第五医学中心收治的初治小肝癌患者80例,其中35例患者接受射波刀治疗,共41个靶病灶; 45例患者接受射频消融治疗,共47个靶病灶。观察两组患者的客观有效率（完全缓解+部分缓解）、1年总生存率、1年局部控制率以及术后不良反应的发生率。计数资料2组间比较采用χ2检验或连续校正χ2检验。生存分析采用Kaplan-Meier法计算局部控制率,并应用log-rank法检验。结果研究共随访6. 0～17. 7个月,中位随访时间13. 5个月,其中2例（2. 5%）患者失访,每组各1例。射波刀组31个病灶（75. 6%）完全缓解,4个病灶（9. 8%）部分缓解,4个病灶（9. 8%）稳定,2个病灶（4. 9%）进展,客观有效率为85. 4%,1年总生存率为100%,1年局部控制率为94. 3%;射频消融组38个病灶（80. 9%）完全缓解,9个病灶（19. 1%）进展,客观有效率为80. 9%,1年总生存率为100%,1年局部控制率为91. 0%。2组客观有效率和局部控制率比较,差异均无统计学意义...
- 癌,肝细胞 /
- 导管消融术 /
- 放射疗法 /
- 治疗结果
Abstract: Objective To investigate the clinical effect and safety of cyberknife versus radiofrequency ablation in the treatment of small hepatocellular carcinoma. Methods A total of 80 previously untreated patients with small hepatocellular carcinoma who were admitted to The Fifth Medical Center of Chinese PLA General Hospital from October 2017 to March 2018 were enrolled. Among these patients, 35 patients with 41 target lesions received cyberknife, and 45 patients with 47 target lesions received radiofrequency ablation. The two groups were compared in terms of objective response rate ( complete remission + partial remission) , 1-year overall survival rate, 1-year local control rate, and incidence rate of postoperative adverse events. The chi-square test or the continuous calibration chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to calculate local control rate, and the log-rank test was used for survival analysis. Results The patients were followed up for 6. 0-17. 7 months, with a median follow-up time of 13. 5 months. Two patients ( 2. 5%) were lost to follow-up, with one patient from each group. In the cyberknife group, there were 31 lesions with complete remission ( 75. 6%) , 4 lesions with partial remission ( 9. 8%) , 4 lesions with a stable state ( 9. 8%) , and 2 lesions with progression ( 4. 8%) , with an objective response rate of 85. 4%, a 1-year overall survival rate of 100%, and a 1-year local control rate of 94. 3%.In the radiofrequency ablation group, there were 38 lesions with complete remission ( 80. 9%) and 9 lesions with progression ( 19. 1%) , with an objective response rate of 80. 9%, a 1-year overall survival rate of 100%, and a 1-year local control rate of 91. 0%. There were no significant differences in objective response rate and local control rate between the two groups ( both P > 0. 05) . Most postoperative adverse events were mild ( grade 1-2) , and no serious adverse events were observed. Conclusion Cyberknife is as safe and effective as radiofrequency ablation in the treatment of small hepatocellular carcinoma and is one of the options for the treatment of small hepatocellular carcinoma.
- carcinoma, hepatocellular /
- catheter ablation /
- radiotherapy /
- treatment outcome

HTML全文

参考文献(26)

[1] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (2) :115-132.

[2] ZUO TT, ZHENG RS, ZENG HM, et al. Analysis of liver cancer incidence and trend in China[J]. Chin J Oncol, 2015, 37 (9) :691-696. (in Chinese) 左婷婷, 郑荣寿, 曾红梅, 等.中国肝癌发病状况与趋势分析[J].中华肿瘤杂志, 2015, 37 (9) :691-696.

[3] YAO SY, ZHOU JP, CHEN YY, et al. Radiofrequency ablation combined with non-specific sequential immunotherapy for early hepatoeellular carcinoma:A prospective study[J]. Chin J Dig Surg, 2018, 17 (4) :377-382. (in Chinese) 姚思扬, 周佳鹏, 陈元元, 等.射频消融术后序贯非特异性免疫治疗早期肝细胞癌的前瞻性研究[J].中华消化外科杂志, 2018, 17 (4) :377-382.

[4] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J]. J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[5] BENEDICT SH, YENICE KM, FOLLOWILL D, et al. Stereotactic body radiation therapy:The report of AAPM Task Group101[J]. Med Phys, 2010, 37 (8) :4078-4101.

[6] TIMMERMAN RD, HERMAN J, CHO LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice[J]. J Clin Oncol, 2014, 32 (26) :2847-2854.

[7] Working Committee of the Guidelines of the Chinese Society of Clinical Oncology. Guidelines of CSCO hepatocellular carcinoma[M]. Beijing:People’s Health Publishing House, 2018:58-64. (in Chinese) 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会原发性肝癌诊疗指南[M].北京:人民卫生出版社, 2018:58-64.

[8] YOON SM, LIM YS, PARK MJ, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma[J]. PLo S One, 2013, 8 (11) :e79854.

[9] SANUKI N, TAKEDA A, OKU Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma:A retrospective outcome analysis in 185 patients[J]. Acta Oncol, 2014, 53 (3) :399-404.

[10] MO HY, ZHONG JH. Comment on stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma[J]. J Surg Oncol, 2016, 113 (6) :715.

[11] HUERTAS A, BAUMANN AS, SAUNIER-KUBS F, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma[J]. Radiother Oncol, 2015, 115 (2) :211-216.

[12] TAKEDA A, SANUKI N, ERIGUCHI T, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2014, 29 (2) :372-379.

[13] PARK JH, YOON SM, LIM YS, et al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2013, 28 (10) :1638-1642.

[14] KWON JH, BAE SH, KIM JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer[J]. BMC Cancer, 2010, 10 (1) :475.

[15] JEONG Y, JUNG J, CHO B, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma[J].BMC Cancer, 2018, 18 (1) :416.

[16] KUO HT, QUE J, LIN LC, et al. Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma[J]. Medicine (Baltimore) , 2017, 96 (50) :e9249.

[17] YEUNG R, BEATON L, RACKLEY T, et al. Stereotactic body radiotherapy for small unresectable hepatocellular carcinomas[J]. Clin Oncol (R Coll Radiol) , 2019, 31 (6) :365-373.

[18] WAHL DR, STENMARK MH, TAO Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J]. J Clin Oncol, 2016, 34 (5) :452-459.

[19] HARA K, TAKEDA A, TSURUGAI Y, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation:A propensity score analysis[J]. Hepatology, 2019.[Epub ahead of print]

[20] SAKURAI H, ISHIKAWA H, OKUMURA T. Proton beam therapy in Japan:Current and future status[J]. Jpn J Clin Oncol, 2016, 46 (10) :885-892.

[21] CULLETON S, JIANG H, HADDAD CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma[J]. Radiother Oncol, 2014, 111 (3) :412-417.

[22] DOI H, SHIOMI H, MASAI N, et al. Threshold doses and prediction of visually apparent liver dysfunction after stereotactic body radiation therapy in cirrhotic and normal livers using magnetic resonance imaging[J]. J Radiat Res, 2016, 57 (3) :294-300.

[23] JANG WI, KIM MS, BAE SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma[J]. Radiat Oncol, 2013, 8 (1) :250.

[24] KATZ AW, CHAWLA S, QU Z, et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma:Clinical outcome and pathologic correlation[J]. Int J Radiat Oncol Biol Phys, 2012, 83 (3) :895-900.

[25] LI TT, SUN J, WANG Q, et al. Clinical effect of stereotactic body radiotherapy in treatment of patients with small hepatocellular carcinoma and related prognostic factors[J]. J Clin Hepatol, 2018, 34 (8) :1702-1706. (in Chinese) 李甜甜, 孙静, 王权, 等.小肝癌立体定向放射治疗的效果及预后分析[J].临床肝胆病杂志, 2018, 34 (8) :1702-1706.

[26] ZHANG T, SUN J, HE WP, et al. Clinical effect of CyberKnife stereotactic radiosurgery in treatment of patients with small hepatocellular carcinoma[J]. J Clin Hepatol, 2017, 33 (4) :694-698. (in Chinese) 张弢, 孙静, 何卫平, 等.射波刀立体定向放射治疗小肝癌的临床效果[J].临床肝胆病杂志, 2017, 33 (4) :694-698.

施引文献

资源附件(0)

访问统计